The pharmaceutical landscape is littered with the market-access failures of recent biotech launches – the reason investors now often “sell on the launch” — innovative science and a biotechs’ vision of “unmet medical need” are often irrelevant or meaningless to payers. Even the earliest target product profile needs to reflect “unmet need” from the payer’s point of view – using an objective, broad and forward-looking understanding of competition — and create a medical and economic roadmap for minimizing payer restrictions.

The Academy of Managed Care Pharmacy (AMCP) is the nation’s leading professional association dedicated to increasing patient access to affordable medicines, improving health outcomes and ensuring the wise use of health care dollars. Through evidence- and value-based strategies and practices, the Academy’s 8,000 pharmacists, physicians, nurses and other practitioners manage medication therapies for the 270 million Americans served by health plans, pharmacy benefit management firms, emerging care models and government.

The FH Global Summit is the only conference dedicated to solving global challenges in the care and treatment of familial hypercholesterolemia (FH) through a multi-stakeholder and interdisciplinary approach. An invitation-only event, the summit features a stellar lineup of speakers and panelists who are experts in FH, genomics, precision medicine, alongside leading healthcare practitioners, individuals with FH and industry.

Cambridge Healthtech Institute’s Seventh Annual, Coverage and Reimbursement for Advanced Diagnostics – Latest Developments in the Dx Reimbursement Landscape. Ammar Qadan, Vice President, Global Market Access, Illumina and Roger Longman, CEO, RealEndpoints present: Addressing the Biggest Commercial Problem in Diagnostics

To explore new models of payment and benefit designs for high-investment medications, the AMCP convened a stakeholder conference in Baltimore Maryland on July 24 and 25, 2018. Health care leaders representing health plans, integrated delivery systems, pharmacy benefit managers, employers, national professional associations, the federal government, and biopharmaceutical companies participated in the forum.

ISPOR is the leading global scientific and educational organization for health economics and outcomes research (HEOR) and its use in decision making to improve health. Our annual conference includes over 5,000 attendess from across the industry.